- Home
- NVCT vs BWAY Comparison
NVCT vs BWAY Comparison
Compare NVCT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCT
- BWAY
- Stock Information
- Founded
- NVCT 2020
- BWAY 2003
- Country
- NVCT United States
- BWAY Israel
- Employees
- NVCT N/A
- BWAY N/A
- Industry
- NVCT Medicinal Chemicals and Botanical Products
- BWAY Medical/Dental Instruments
- Sector
- NVCT Health Care
- BWAY Health Care
- Exchange
- NVCT Nasdaq
- BWAY Nasdaq
- Market Cap
- NVCT 184.9M
- BWAY 201.1M
- IPO Year
- NVCT 2022
- BWAY 2019
- Fundamental
- Price
- NVCT $7.26
- BWAY $12.98
- Analyst Decision
- NVCT Strong Buy
- BWAY Strong Buy
- Analyst Count
- NVCT 3
- BWAY 2
- Target Price
- NVCT $17.00
- BWAY $14.25
- AVG Volume (30 Days)
- NVCT 186.4K
- BWAY 53.0K
- Earning Date
- NVCT 08-05-2025
- BWAY 08-05-2025
- Dividend Yield
- NVCT N/A
- BWAY N/A
- EPS Growth
- NVCT N/A
- BWAY N/A
- EPS
- NVCT N/A
- BWAY 0.08
- Revenue
- NVCT N/A
- BWAY $43,457,000.00
- Revenue This Year
- NVCT N/A
- BWAY $351.53
- Revenue Next Year
- NVCT N/A
- BWAY $21.84
- P/E Ratio
- NVCT N/A
- BWAY $62.68
- Revenue Growth
- NVCT N/A
- BWAY 26.86
- 52 Week Low
- NVCT $4.44
- BWAY $5.67
- 52 Week High
- NVCT $11.80
- BWAY $13.48
- Technical
- Relative Strength Index (RSI)
- NVCT 29.72
- BWAY 72.08
- Support Level
- NVCT $7.84
- BWAY $10.84
- Resistance Level
- NVCT $8.27
- BWAY $13.35
- Average True Range (ATR)
- NVCT 0.45
- BWAY 0.51
- MACD
- NVCT -0.08
- BWAY 0.16
- Stochastic Oscillator
- NVCT 6.12
- BWAY 86.11
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.